Posted by Michael Wonder on 20 Nov 2021
MHRA authorises Vumerity for multiple sclerosis patients
19 November 2021 - The MHRA has granted marketing authorisation for diroximel fumarate as oral treatment for relapsing-remitting multiple sclerosis.
Vumerity (diroximel fumarate) is a next-generation oral fumarate treatment for adults with relapsing-remitting multiple sclerosis.
